openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizie

News

Discover

Markets

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizie

LEO Pharma — news, coverage & facts — IJR

|NewsJournalsOrganizationLEO Pharma

Organization

LEO Pharma

0 members

Feed News Media Community Map About

1 mentions · 24hcoverage spread: L27/C32/R41

Comments

Ask this entity anything:

Free account · your comment posts right after signup

Photo: Jonathan Borba / Wikimedia Commons (Pexels)
LEO Pharma plans $435M Dersimelagon rights deal
LEO Pharma agreed to acquire worldwide rights to dersimelagon from Tanabe Pharma for up to $435 million, aiming to bring a late-stage oral MC1R agonist for EPP and XLP to market pending FDA approval. The deal reflects LEO’s strategy to grow its medical dermatology portfolio, backed by Phase 3 results, fast-track and orphan drug designations, and a planned 2027 launch if approved.
5 sources

Facts from Wikidata (CC0).

LEO Pharma A/S is a multinational Danish pharmaceutical company, founded in 1908, with a presence in about 100 countries. Its headquarters are in Ballerup, near Copenhagen The company is 100% integrated into a private foundation owned by the LEO Foundation. LEO Pharma develops and markets products for dermatology, bone remodeling thrombosis and coagulation. In 1945, it was the first producer of penicillin outside the US and UK.

Read the full article →